Most companies continue to have enormous opportunities to improve in many areas of working capital (WC), suggests EY research. A high-level comparative analysis indicates that the leading 1,500 US and European companies, many PE-backed, may have as much as US$2.5 trillion in excess WC, over and above the level they require to operate their business model efficiently and meet all their operating requirements. This figure is equivalent to nearly 10% of their combined sales. In other words, for every US$1b in sales, the opportunity for WC improvement is, on average, US$100m.
Technology and healthcare are still a focus
Technology has been the infallible sector of PE deal making over the past five years, driving 40% of overall volume and a third of total capital invested by PE firms. With cloud computing and mobile technology markets maturing, sponsors are looking to invest in emerging verticals such as artificial intelligence (AI) and machine learning (ML), robotic process automation (RPA), internet of things (IoT), robotics, drones, blockchain, and virtual reality. A standout area in emerging tech plays has been smart mobility, with $120b invested over the last 24 months.
Despite the headlines in emerging technologies, software as a service (SaaS) companies continue to drive the bulk of tech sector deal volume, given the potential for recurring revenue streams to buoy debt-funded buyouts. While the SaaS subscription revenue model provides assurance in earnings predictability, PE firms should be aware of WC hurdles to the delivery cash flow benefits to ultimately fuel the next portfolio investment.
Healthcare is just behind tech, with deal volume and value both growing at a 12%-13% CAGR from 2014-2018, including four megadeals of over $4B. The US healthcare market has outpaced GDP growth for decades, with pharmaceutical companies presenting attractive buy-and-build opportunities for PE funds. New sub-sector business models in behavioral health and healthcare tech are expected to be key focus areas, with a projected growth rate of 14% through 2023. Healthcare investments present sector-specific WC challenges — including insurance, legislative change, and costly product development cycles – warranting a keen focus on cash management.